The Patent Finder
RP

Regeneron Pharmaceuticals, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

1,303 patents currently held

52 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
110
Ending by 2030
Dec 2026
Next term end
604
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 17 fees due Dec 2 to 30, 2026 · next Dec 2
  • 19 fees due Jan 4 to 28, 2027 · next Jan 4
  • 26 fees due Feb 1 to 28, 2027 · next Feb 1
  • 23 fees due Mar 1 to 26, 2027 · next Mar 1
  • 32 fees due Apr 1 to 30, 2027 · next Apr 1
  • 23 fees due May 3 to 28, 2027 · next May 3
  • 27 fees due Jun 3 to 30, 2027 · next Jun 3
  • 25 fees due Jul 5 to 30, 2027 · next Jul 5
  • 24 fees due Aug 4 to 27, 2027 · next Aug 4
  • 18 fees due Sep 1 to 26, 2027 · next Sep 1
  • 32 fees due Oct 2 to 30, 2027 · next Oct 2
  • 9 fees due Nov 5 to 14, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 604 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 7,531,172Methods of Treating Diseases with a VEGF Antagonist
In force
 · High confidence
In forceHigh confidence
US 7,732,167Interferon-Alpha/Beta Binding Fusion Proteins and Therapeutic Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 7,608,430Interferon-Gamma Antagonists and Therapeutic Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 8,080,248Method of Treating Rheumatoid Arthritis with an IL-6R Antibody
In force
 · High confidence
In forceHigh confidence
US 8,183,014High Affinity Antibodies to Human IL-6 Receptor
In force
 · High confidence
In forceHigh confidence
US 8,192,741Method of Treating Rheumatoid Arthritis with an ANTI-IL-6R Antibody
In force
 · High confidence
In forceHigh confidence
US 8,568,721Method of Treating Rheumatoid Arthritis with an Anti-IL-6R Antibody
In force
 · High confidence
In forceHigh confidence
US 9,308,256Method of Treating Rheumatoid Arthritis With An Anti-IL-6R Antibody
In force
 · Medium confidence
In forceMedium confidence
US 9,884,916High Affinity Antibodies to Human IL-6 Receptor
In force
 · Medium confidence
In forceMedium confidence
US 10,584,173Nucleic Acids Encoding High Affinity Antibodies to Human IL-6 Receptor
In force
 · High confidence
In forceHigh confidence
10 of 1,303 patents shown.
Pro members see all 1,303.
Pro members: see all 1,303 patents
Also on record, not counted in the 1,303: 52 patents in force now held by others · 151 patents ended · 838 applications pending · 436 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited